All In Biotech

Drug Trial Radar · NCT04282980

A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)

A Multicenter Phase 2, Single-Arm Open-Label Study of DCC-2618 to Assess Efficacy, Safety, and Pharmacokinetics In Patients With Advanced Gastrointestinal Stromal Tumors Who Have Progressed On Prior Anticancer Therapies.

Last checked: Nov 19, 2026Latest source record: Mar 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

39

Actual

Start

Apr 23, 2020

Primary completion

Feb 26, 2021

Study completion Aug 23, 2022

Sponsor

Lead sponsor
Zai Lab (Shanghai) Co., Ltd.Industry
Sponsor type
Industry
First posted
Feb 25, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this trial is to evaluate the progress free survival (PFS) of DCC-2618 in patients with advanced gastrointestinal stromal tumors who have progressed with prior anticancer therapies based on independent radiologic review.

Conditions

  • Gastrointestinal Stromal Tumors

Interventions

  • DCC-2618Drug

    Oral kinase inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Approximately 10 months since the first subject enrolled.

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Chinese People's Liberation Army General Hospital

    Beijing, Beijing Municipality, China

  • Union Medical College Hospital, Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Union Medical College Hospital, Fujian Medical University

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • The Sixth Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Fudan University Cancer Hospital

    Shanghai, Shanghai Municipality, China

  • Renji Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.